China Pharma Holdings (CPHI) Share-based Compensation (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Share-based Compensation came in at $15.0 million in Q1 2026, down 3.08% on a QoQ basis from $15.5 million in Q4 2025.
China Pharma Holdings (CPHI) Share-based Compensation (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 12 years of Share-based Compensation data on file, last reported at $15.0 million in Q1 2026.
- Quarterly Share-based Compensation changed N/A year-over-year to $15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.8 million (changed N/A YoY) and the FY2025 annual result came in at $17.9 million, up 384.88% from the prior year.
- Share-based Compensation retreated to $15.0 million in Q1 2026, from $15.5 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $15.5 million in Q4 2025 to a low of -$491074.0 in Q2 2023.
- A 5-year average of $3.1 million and a median of $828726.0 in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 194014.07% — and 2023, when it plunged 345.54%.
- Tracing CPHI's Share-based Compensation over 5 years: stood at $1.0 million in 2022, then plunged by 140.7% to -$410000.0 in 2023, then soared by 668.29% to $2.3 million in 2024, then jumped by 563.95% to $15.5 million in 2025, then slipped by 3.08% to $15.0 million in 2026.
- The last three Share-based Compensation figures came in at $15.0 million (Q1 2026), $15.5 million (Q4 2025), and $2.3 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | China Pharma Holdings | 42.70 Mn | 42.39 Mn | 83,566.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.99 Mn |
| Mar 31, 2026 | 14.99 Mn |
| Dec 31, 2025 | 15.47 Mn |
| Dec 31, 2025 | 15.47 Mn |
| Dec 31, 2024 | 2.33 Mn |
| Dec 31, 2024 | 2.33 Mn |
| Mar 31, 2024 | 1.37 Mn |
| Mar 31, 2024 | 1.37 Mn |
| Dec 31, 2023 | -410,000.00 |
| Dec 31, 2023 | -410,000.00 |
| Sep 30, 2023 | 1.90 Mn |
| Sep 30, 2023 | 1.90 Mn |
| Jun 30, 2023 | -491,074.00 |
| Jun 30, 2023 | -491,074.00 |
| Mar 31, 2023 | 650,000.00 |
| Mar 31, 2023 | 650,000.00 |
| Dec 31, 2022 | 1.01 Mn |
| Dec 31, 2022 | 1.01 Mn |
| Sep 30, 2022 | 200,000.00 |
| Sep 30, 2022 | 200,000.00 |